These underappreciated biotechnology start-ups could turn heads one day -- but not yet.
News & Analysis: Axovant Gene Therapies Ltd.
The small-cap biopharma started 2019 with a rising stock price and a new focus on gene therapies, but it's been a rocky transition.
The biopharma is wisely taking advantage of its lofty stock price to raise capital through a share offering.
Investors are excited about new clinical results suggesting the small-cap biopharma is on to something big.
The biopharma's wild year continues with another clinical failure, but it won't have much impact on the company's future.
The meteoric rise in recent weeks is proving unsustainable.
Find out why these stocks got smacked down the hardest.
Can these red-hot drug stocks keep the momentum going?
Find out what tasty news one restaurant chain offered to investors.
Can the company treat Parkinson's disease with gene therapy?